Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


B&L Hydroview IOL Approvable Vote Includes Modification To Incision Size

This article was originally published in The Gray Sheet

Executive Summary

Bausch & Lomb's Hydroview Model H60M intraocular lens (IOL) is approvable for refilling the functionally intact human capsule following cataract removal provided labeling include a recommended mean incision size of 3.9 mm (+/- 2 standard deviations), FDA's Ophthalmic Devices Panel unanimously agreed (12-0) at its July 23 meeting.

You may also be interested in...

Amplifon Enters U.S. Hearing Care Market As Bausch & Lomb Bows Out

Privately held Italian hearing care firm Amplifon S.p.A. is gaining access to the American market through the acquisition of the Miracle-Ear hearing aid business from Bausch & Lomb. Announced July 12, the deal is expected to close by the end of the summer.

Arcadia Stubs Toe In Nail Fungus Ad Challenge, Giving Advantice Foot In Door On Appeal

Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.

Former MiMedX Execs Convicted On Securities Fraud Charges

The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts